Patents by Inventor Brian Wattenberg

Brian Wattenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070071752
    Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.
    Type: Application
    Filed: September 26, 2006
    Publication date: March 29, 2007
    Applicant: Johnson & Johnson Pharmaceutical R and D LLC
    Inventors: Stuart Pitson, Brian Wattenberg, Pu Xia, Richard D'Andrea, Jennifer Gamble, Matthew Vadas
  • Patent number: 7172879
    Abstract: The invention relates to detection of sphingosine kinase activity and sphingosine kinase agonist or antagonist activity.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: February 6, 2007
    Assignee: Johnson & Johnson Pharmaceutical Research & Development LLP
    Inventors: Jennifer Gamble, Mathew Vadas, Pu Xia, Philip Barter, Kerry Anne Rye, Brian Wattenberg, Stuart Pitson
  • Publication number: 20050074830
    Abstract: The present invention relates generally to a method of modulating cellular activity and agents useful for same. More particularly, the present invention contemplates a method of modulating endothelial cell activity and even more particularly endothelial cell adhesion molecule expression. Most particularly, the present invention provides a method of treating coronary heart disease by preventing or reducing endothelial cell adhesion molecule expression.
    Type: Application
    Filed: October 7, 2003
    Publication date: April 7, 2005
    Inventors: Jennifer Gamble, Mathew Vadas, Pu Xia, Phillip Barter, Kerry-Anne Rye, Brian Wattenberg, Stuart Pitson
  • Patent number: 6649362
    Abstract: A screening method for identifying a therapeutic candidate for a coronary heart disease or an inflammatory condition is disclosed. The screening method tests for the presence or absence of an effect by a putative therapeutic agent on a component of a sphingosine kinase signaling pathway.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: November 18, 2003
    Assignee: Medvet Science Pty. Ltd.
    Inventors: Jennifer Gamble, Mathew Vadas, Pu Xia, Phillip Barter, Kerry-Anne Rye, Brian Wattenberg, Stuart Pitson
  • Publication number: 20020051777
    Abstract: The present invention relates generally to a method of modulating cellular activity and agents useful for same. More particularly, the present invention contemplates a method of modulating endothelial cell activity and even more particularly endothelial cell adhesion molecule expression. Most particularly, the present invention provides a method of treating coronary heart disease by preventing or reducing endothelial cell adhesion molecule expression.
    Type: Application
    Filed: October 16, 2001
    Publication date: May 2, 2002
    Inventors: Jennifer Gamble, Mathew Vadas, Pu Xia, Phillip Barter, Kerry-Anne Rye, Brian Wattenberg, Stuart Pitson